Results 41 to 50 of about 854 (146)
, 2023 Background: Following the CENTURION phase 3 randomized controlled trial’s four-month double-blind phase, this 12-month open-label extension collected data for up to one year about dose optimization, patterns of use, migraine-related disability, and ...
Ruff, Dustin +6 more
core +1 more source
The 5-HT receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials [PDF]
, 2012 Lasmiditan is a novel selective 5-HT(1F) receptor agonist. It is both scientifically and clinically relevant to review whether a 5-HT(1F) receptor agonist is effective in the acute treatment of migraine. Two RCTs in the phase II development of lasmiditan
Jes Olesen +3 more
core +1 more source
, 2022 Some migraine treatments are contraindicated for patients with cardiovascular disease (CVD) or risk factors (CVRFs). We report safety and efficacy of lasmiditan, a new oral acute migraine treatment with no cardiovascular contraindication, in Japanese ...
Mika Komori (114112) +4 more
core +1 more source
Lasmiditan: the first neurally acting anti-migraine drug [PDF]
, 2021 Lasmiditan is the first neurally acting drug for the treatment of acute migraine. It is a highly selective, orally acting 5-HT1F agonist that was approved in November 2019, for the acute treatment of migraine in adults, with or without aura, by USFDA ...
Mahajan, Sonia S. +5 more
core +1 more source
, 2023 BackgroundSerotonin syndrome (SS) symptoms overlap with adverse events associated with lasmiditan, a 5-HT (serotonin)1F receptor agonist for acute treatment of migraine.
Sheila I. Miller (17293762) +5 more
core +1 more source
Lasmiditan: an additional therapeutic option for the acute treatment of migraine
, 2021 Introduction: Migraine is currently listed as the second cause of ‘years lived with disability’ and the sixth cause of global disability. Despite the burden associated to the disease, availability of specific drugs is still limited.
Martinelli D. +5 more
core +1 more source
, 2023 Background: We performed a random-effects network meta-analysis to study the efficacy and safety of newly developed drugs for the acute treatment of migraine attacks. Methods: MEDLINE via PubMed, Embase and The Cochrane Register of Controlled Trials were
Goadsby, Peter J +13 more
core +1 more source
, 2022 Additional file 1: Supplementary Figure 1. Involvement of the 5-HT1B and 5-HT1D receptors in the effect of Lasmiditan. Before the addition of 30 μM Lasmiditan, 300 nM of GR127935, a 5HT1B/5HT1D blocker was added to the TG which subsequently stimulated ...
Karin Warfvinge (407987) +7 more
core +1 more source
Rational Use of Lasmiditan for Acute Migraine Treatment in Adults: A Narrative Review
, 2021 Purpose: This narrative review provides an update on the research that led to the development of ditans and lasmiditan for the acute treatment of migraine in adults and discusses the potential advantages and disadvantages of lasmiditan in clinical use ...
Ferrari, Anna +3 more
core +1 more source
Plasma amylin levels in migraine and after erenumab treatment: A REFORM study
Headache: The Journal of Head and Face Pain, EarlyView.Plain Language Summary Researchers are searching for blood tests that can show what is happening in migraine and help predict who will benefit from preventive treatment, and blood amylin (a signaling molecule known to trigger migraine) has been shown to be elevated in people with chronic migraine.
Rogelio Domínguez‐Moreno +8 more
wiley +1 more source